Exactly. KAVL is such a rare OTC stock. You don't get chances like this very often, especially with a company that generates $40M+ a quarter, and estimates over $400M for the year, with Nasdaq uplisting coming, new distribution deals on the horizon, new products, FDA approval, etc.
To me, this looks like the big boys are being patient, waiting for people to sell to them. For the first 6 weeks of the year we averaged 3.5M shares traded each week. The last 3 weeks we've seen less than 1.5M shares trade and yet we're holding up pretty well. That tells me, next 3.5M share week sends this up to new highs.
News 
Market Data 
Discover 
